4584.TKidswell Bio Corporation
Nov 12, 2026 — Q2 2027 Earnings Release
Chart by TradingViewThe schedule
- Thu12Nov
Kidswell Bio is expected to report Q2 2027 results, providing an update on biosimilar revenues and the accelerating cash burn from clinical R&D.
- Tue15Dec
Anticipated Phase 1/2 clinical progress update for the company's proprietary SHED (stem cells from human exfoliated deciduous teeth) therapy.
- Fri12Feb
Q3 earnings will serve as a crucial reality check on the balance sheet and cash runway as late-stage R&D scales up.
- Wed31Mar
Targeted fiscal year-end timeline for potential new biosimilar out-licensing or contract manufacturing agreements.
- Thu13May
Full-year results and initial FY2028 guidance, focusing on the trajectory toward operating profitability.
- Thu15Jul
Anticipated regulatory submission of the formal clinical trial plan to the PMDA for corporate-sponsored SHED cell therapy trials.
- Thu12Aug